These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32460208)

  • 1. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.
    Gigante A; Aquili A; Farinelli L; Caraffa A; Ronconi G; Enrica Gallenga C; Tetè G; Kritas SK; Conti P
    Med Hypotheses; 2020 Oct; 143():109856. PubMed ID: 32460208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
    Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palmitoylethanolamide (PEA) Inhibits SARS-CoV-2 Entry by Interacting with S Protein and ACE-2 Receptor.
    Fonnesu R; Thunuguntla VBSC; Veeramachaneni GK; Bondili JS; La Rocca V; Filipponi C; Spezia PG; Sidoti M; Plicanti E; Quaranta P; Freer G; Pistello M; Mathai ML; Lai M
    Viruses; 2022 May; 14(5):. PubMed ID: 35632821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized clinical trial "olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin": preliminary results.
    D'Ascanio L; Vitelli F; Cingolani C; Maranzano M; Brenner MJ; Di Stadio A
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4156-4162. PubMed ID: 34156697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
    Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
    J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
    Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
    Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.
    Grimes JM; Grimes KV
    J Mol Cell Cardiol; 2020 Jul; 144():63-65. PubMed ID: 32422320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation.
    Roncati L; Lusenti B; Pellati F; Corsi L
    Prostaglandins Other Lipid Mediat; 2021 Jun; 154():106540. PubMed ID: 33636368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
    Almerie MQ; Kerrigan DD
    Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultramicronized Palmitoylethanolamide in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation.
    D'Amico R; Monaco F; Siracusa R; Cordaro M; Fusco R; Peritore AF; Gugliandolo E; Crupi R; Cuzzocrea S; Di Paola R; Impellizzeri D; Genovese T
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution.
    Skaper SD; Facci L; Barbierato M; Zusso M; Bruschetta G; Impellizzeri D; Cuzzocrea S; Giusti P
    Mol Neurobiol; 2015 Oct; 52(2):1034-42. PubMed ID: 26055231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody.
    Gebremeskel S; Schanin J; Coyle KM; Butuci M; Luu T; Brock EC; Xu A; Wong A; Leung J; Korver W; Morin RD; Schleimer RP; Bochner BS; Youngblood BA
    Front Immunol; 2021; 12():650331. PubMed ID: 33777047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired Duodenal Palmitoylethanolamide Release Underlies Acid-Induced Mast Cell Activation in Functional Dyspepsia.
    Sarnelli G; Pesce M; Seguella L; Lu J; Efficie E; Tack J; Elisa De Palma FD; D'Alessandro A; Esposito G
    Cell Mol Gastroenterol Hepatol; 2021; 11(3):841-855. PubMed ID: 33065341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.
    Conti P; Gallenga CE; Tetè G; Caraffa A; Ronconi G; Younes A; Toniato E; Ross R; Kritas SK
    J Biol Regul Homeost Agents; 2020 March-April,; 34(2):333-338. PubMed ID: 32228825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis.
    Abramo F; Campora L; Albanese F; della Valle MF; Cristino L; Petrosino S; Di Marzo V; Miragliotta V
    BMC Vet Res; 2014 Jan; 10():21. PubMed ID: 24423192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.
    Conti P; Ronconi G; Caraffa A; Gallenga CE; Ross R; Frydas I; Kritas SK
    J Biol Regul Homeost Agents; 2020 March-April,; 34(2):327-331. PubMed ID: 32171193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.
    Chen X; Guo H; Qiu L; Zhang C; Deng Q; Leng Q
    Front Immunol; 2020; 11():2056. PubMed ID: 32973814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H
    Yang G
    Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.